Literature DB >> 11331147

Reversal of diminished inhibitory sensory gating in cocaine addicts by a nicotinic cholinergic mechanism.

L E Adler1, A Olincy, E Cawthra, M Hoffer, H T Nagamoto, L Amass, R Freedman.   

Abstract

Cocaine addiction, as with other stimulant abuse, produces psychotic symptoms. Although often moderate to mild in severity, these symptoms are, nevertheless, associated with poorer over-all outcome. Recent studies suggest diminished nicotinic cholinergic neurotransmission as a mechanism of a physiological deficit found in schizophrenia, failure of auditory sensory inhibition. Diminished inhibitory sensory gating also occurs in cocaine addicts, probably because of their increased catecholaminergic neurotransmission, which blocks the inhibition. In the present study, 11 cocaine addicts in the first week of detoxification were recorded electrophysiologically, after which the effects of 6 mg of nicotine gum, were assessed in a double-blind placebo-controlled crossover design. The test was repeated 10 days later. Treatment with nicotine, but not placebo, briefly reversed the inhibitory abnormality on both test days. Although nicotine itself may not be a desirable therapeutic agent, because desensitization of nicotinic receptors limits the time course of its effect, the study identifies a previously unexploited therapeutic target for new drug development for the neuropsychiatric sequelae of cocaine addiction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331147     DOI: 10.1016/S0893-133X(00)00242-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  9 in total

1.  Gamma and beta neural activity evoked during a sensory gating paradigm: effects of auditory, somatosensory and cross-modal stimulation.

Authors:  Michael A Kisley; Zoe M Cornwell
Journal:  Clin Neurophysiol       Date:  2006-09-27       Impact factor: 3.708

2.  Visual emotional stimuli modulation of auditory sensory gating studied by magnetic P50 suppression.

Authors:  Hidehisa Yamashita; Yasumasa Okamoto; Shigeru Morinobu; Shigeto Yamawaki; Seppo Kähkönen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

3.  The neural networks underlying auditory sensory gating.

Authors:  A R Mayer; F M Hanlon; A R Franco; T M Teshiba; R J Thoma; V P Clark; J M Canive
Journal:  Neuroimage       Date:  2008-08-29       Impact factor: 6.556

4.  Differential relationships of impulsivity or antisocial symptoms on P50, N100, or P200 auditory sensory gating in controls and antisocial personality disorder.

Authors:  Marijn Lijffijt; Blake Cox; Michelle D Acas; Scott D Lane; F Gerard Moeller; Alan C Swann
Journal:  J Psychiatr Res       Date:  2012-03-31       Impact factor: 4.791

5.  Neurobehavioural deficits associated with apoptotic neurodegeneration and vulnerability for ADHD.

Authors:  Anders Fredriksson; Trevor Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

6.  Single unit and population responses during inhibitory gating of striatal activity in freely moving rats.

Authors:  H C Cromwell; A Klein; R P Mears
Journal:  Neuroscience       Date:  2007-02-22       Impact factor: 3.590

Review 7.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

8.  The stereotypy-inducing and OCD-like effects of chronic 'binge' cocaine are modulated by distinct subtypes of nicotinic acetylcholine receptors.

Authors:  A Metaxas; Hl Keyworth; Jh Yoo; Y Chen; I Kitchen; A Bailey
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

9.  Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial.

Authors:  Pim R A Heckman; Marlies A Van Duinen; Arjan Blokland; Tolga Uz; Jos Prickaerts; Anke Sambeth
Journal:  Psychopharmacology (Berl)       Date:  2017-11-03       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.